(Q36175903)

12 August 2017

1 reference

title

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature (English)

1 reference

12 August 2017

David J Torgerson

3

0 references

author name string

Rachael L Fleurence

series ordinal

1

1 reference

12 August 2017

Cynthia P Iglesias

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

25 June 2005

1 reference

Osteoporosis International

12 August 2017

published in

1 reference

12 August 2017

volume

17

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

29-40

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-005-1943-z

12 August 2017

exact match

0 references

cites work

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial

1 reference

12 December 2020

Randomized controlled trial of hip protectors among women living in the community.

1 reference

12 December 2020

Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy.

1 reference

12 December 2020

Effect and offset of effect of treatments for hip fracture on health outcomes

1 reference

12 December 2020

Modelling in economic evaluation: an unavoidable fact of life

1 reference

12 December 2020

A COMPARISON OF THE EFFECTIVENESS AND COST OF TREATMENT FOR VERTEBRAL FRACTURES IN WOMEN

1 reference

12 December 2020

The cost utility of bisphosphonate treatment in established osteoporosis

1 reference

12 December 2020

Cost-effectiveness of hormone replacement therapy in the menopause.

1 reference

12 December 2020

An economic analysis of external hip protector use in ambulatory nursing facility residents

1 reference

12 December 2020

Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis

1 reference

12 December 2020

HRT: an analysis of benefits, risks and costs

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

12 Cost-effectiveness of hormone replacement therapy after the menopause

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents.

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial

1 reference

12 December 2020

Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium

1 reference

12 December 2020

Cost-effectiveness of preventing hip fracture in the general female population.

1 reference

12 December 2020

Cost-effectiveness of hormone replacement

1 reference

12 December 2020

Using Economics to Prioritize Research: A Case Study of Randomized Trials for the Prevention of Hip Fractures Due to Osteoporosis

1 reference

12 December 2020

Perimenopausal bone density screening--will it help prevent osteoporosis?

1 reference

12 December 2020

Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application

1 reference

12 December 2020

The economics of osteoporosis and its prevention. A review

1 reference

12 December 2020

Cost-effectiveness of fracture prevention treatments in the elderly.

1 reference

12 December 2020

Estrogen plus progestin and the risk of coronary heart disease

1 reference

12 December 2020

Cost-effectiveness of fracture prevention in established osteoporosis.

1 reference

12 December 2020

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden

1 reference

12 December 2020

Targeting high-risk populations.

1 reference

12 December 2020

Pharmacoeconomic analysis of osteoporosis treatment with risedronate.

1 reference

12 December 2020

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

1 reference

12 December 2020

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

1 reference

12 December 2020

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care

1 reference

12 December 2020

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

Cost-effectiveness of hip protectors in institutional dwelling elderly.

1 reference

12 December 2020

Estrogen use in postmenopausal women--costs, risks, and benefits

1 reference

12 December 2020

Cost and effectiveness of hip protectors among the elderly

1 reference

12 December 2020

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden

1 reference

12 December 2020

Economic evaluation of osteoporosis prevention

1 reference

12 December 2020

Postmenopausal hormones--therapy for symptoms only

1 reference

12 December 2020

Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk

1 reference

12 December 2020

Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative

1 reference

12 December 2020

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

1 reference

12 December 2020

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

1 reference

12 December 2020

Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study

1 reference

12 December 2020

Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease

1 reference

12 December 2020

A cost-effectiveness analysis of hormone replacement therapy in the menopause

1 reference

12 December 2020

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

1 reference

12 December 2020

Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments

1 reference

12 December 2020

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture

1 reference

12 December 2020

Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

1 reference

12 December 2020

Mortality, morbidity, and assessment of fracture risk in male osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

[A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture]

1 reference

12 December 2020

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

1 reference

12 December 2020

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial

1 reference

12 December 2020

Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women

1 reference

12 December 2020

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

1 reference

12 December 2020

Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation

1 reference

12 December 2020

Hormone replacement therapy in a risk-benefit perspective.

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1007/S00198-005-1943-Z

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lftm53i26zfdlnoqmihbj325c4

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_lftm53i26zfdlnoqmihbj325c4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lftm53i26zfdlnoqmihbj325c4

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/lftm53i26zfdlnoqmihbj325c4

1 reference

30 July 2022